Blueprint Medicines (NASDAQ:BPMC) Upgraded to “Outperform” at Oppenheimer
Oppenheimer upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a market perform rating to an outperform rating in a report issued on Friday, MarketBeat.com reports. The brokerage currently has $85.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on BPMC. StockNews.com initiated coverage on shares of […]
More Stories
The Map of Longing: Release Date, Cast Members, Trailer, and Synopsis
Are you ready for an emotional and loving journey between two sisters? If you are a fan of a chaotic...
Netflix has announced the Release Date for Steps, a Cinderella Spin-Off
Mark your calendar! Netflix has brought an all-new anime film, Steps, for a 2026 release. The film flips the classic...
Avatar: The Last Airbender Season 3: Release Date, Trailer, and Cast Members
Everyone’s favourite animated series, Avatar: The Last Airbender, is coming back with more action-packed visuals to captivate its audience once...
Cyberpunk: Edgerunners Season 2: Release Date, Cast, Trailer, and More
Night City is coming again with its renewal after four years of waiting. Since its first release in 2022, the...
Sakamoto Days Season 2: Release Date, Trailer, and Where to Watch?
Sakamoto Days, the 2025 series, is coming back! For Sakamoto Days fans, the blend of action, comedy, and adventure is...
Is Blue Eye Samurai Season 2 Announced? Release Date, Trailer, and More
Netflix’s adult anime series, Blue Eye Samurai, first premiered in 2023 and has quickly become one of the most acclaimed...